Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...
Dealbreaker on MSN
Pfizer pockets $1.9B by offloading stake in HIV drugs company majority owned by GSK
Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.
The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.
Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results